Drugs & Targets FDA grants priority review to Tibsovo in combination with azacitidine in previously untreated IDH1-mutated AML March 11, 2022Vol.48 No.10
Drugs & Targets FDA clinical trial guidances touch on Biden administration’s goals for advancing development of cancer treatments March 11, 2022Vol.48 No.10
Drugs & Targets Six months after court-ordered deadline, FDA hasn’t ruled on major e-cigarette manufacturers’ product applications, advocates say March 11, 2022Vol.48 No.10
Drugs & Targets MGH, Lunaphore to develop spatial biology-based cancer diagnostics February 25, 2022Vol.48 No.08
Drugs & Targets FDA grants Fast Track designation to IO-202, anti-LILRB4 myeloid checkpoint inhibitor for AML February 18, 2022Vol.48 No.07
Drugs & Targets Foundation Medicine to develop companion diagnostics for Lilly’s Retevmo and Loxo Oncology at Lilly’s pipeline February 11, 2022Vol.48 No.06
Drugs & Targets FDA investigating possible increased risk of death with lymphoma drug Ukoniq February 04, 2022Vol.48 No.05
Drugs & Targets Veru, Eli Lilly to evaluate enobosarm + Verzenio in phase III ENABLAR-2 trial February 04, 2022Vol.48 No.05
Drugs & Targets FDA grants fast track designation for enobosarm in AR+ ER+ HER2- metastatic breast cancer January 14, 2022Vol.48 No.02
Drugs & Targets Carisma, Moderna to develop CAR-M therapies for cancer in $45M deal January 14, 2022Vol.48 No.02
